Search hospitals > Florida > Miami
University of Miami Miller School of Medicine
Claim this profileMiami, Florida 33136
Global Leader in Human Immunodeficiency Virus Infection
Global Leader in Multiple Sclerosis
Conducts research for Fibrosis
Conducts research for HIV/AIDS
Conducts research for Cystic Fibrosis
369 reported clinical trials
22 medical researchers
Summary
University of Miami Miller School of Medicine is a medical facility located in Miami, Florida. This center is recognized for care of Human Immunodeficiency Virus Infection, Multiple Sclerosis, Fibrosis, HIV/AIDS, Cystic Fibrosis and other specialties. University of Miami Miller School of Medicine is involved with conducting 369 clinical trials across 405 conditions. There are 22 research doctors associated with this hospital, such as Sabine s Coppieters, MD, Marilyn Huang, Cynthia Levy, MD, and Paul Martin, MD.Area of expertise
1Human Immunodeficiency Virus Infection
Global Leader2Multiple Sclerosis
Global LeaderEULAR
ACR
Top PIs
Sabine s Coppieters, MDInvestigator site 2 - US00100872 years of reported clinical research
Studies Myasthenia Gravis
Studies Muscle Weakness
25 reported clinical trials
13 drugs studied
Marilyn HuangUniversity of Miami3 years of reported clinical research
Studies Ovarian Cancer
Studies Ovarian Tumors
13 reported clinical trials
39 drugs studied
Cynthia Levy, MDUniversity of Miami Miller School of Medicine1 year of reported clinical research
Studies Cholangitis
Studies Liver Cirrhosis
12 reported clinical trials
12 drugs studied
Paul Martin, MDUniversity of Miami6 years of reported clinical research
Studies Hepatitis
Studies Liver Cirrhosis
9 reported clinical trials
11 drugs studied
Clinical Trials running at University of Miami Miller School of Medicine
Multiple Sclerosis
Traumatic Brain Injury
Diffuse Large B-Cell Lymphoma
Alopecia Areata
Systemic Lupus Erythematosus
Hodgkin's Lymphoma
Lymphoma
Hair Loss
Pathology
Medication Adherence
Ofatumumab
for Multiple Sclerosis
The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have participated in a Novartis ofatumumab clinical MS study. Vaccination sub-study The purpose of this research sub-study is to find out the effects of ofatumumab on the development of antibody responses to selected vaccines and keyhole limpet hemocyanin (KLH) neo-antigen in subjects with relapsing multiple sclerosis (RMS).
Recruiting2 awards Phase 3
Remibrutinib vs Teriflunomide
for Multiple Sclerosis
This trial compares two medications, remibrutinib and teriflunomide, for treating patients with relapsing multiple sclerosis. These patients have repeated episodes of symptoms and need effective treatments. The medications work by controlling the immune system to prevent it from causing damage to the nervous system. Teriflunomide is an approved medication for adults with relapsing multiple sclerosis.
Recruiting2 awards Phase 3
BIIB091
for Relapsing Multiple Sclerosis
In this study, researchers will learn more about a study drug called BIIB091 in participants with MS who may be experiencing relapses. It is a 2-part study. In Part 1, one set of participants will take either BIIB091 or diroximel fumarate (DRF). In Part 2, a different set of participants will take either a combination of BIIB091 and DRF or DRF alone. The goal of the study is to learn more about the safety of BIIB091 and to compare the effects of the study drug when taken alone or together with DRF. The main question researchers are trying to answer are: * How many participants have new or worsening medical problems (adverse events) after taking BIIB091 or DRF? * How many new areas of inflammation occur in the brain after treatment with BIIB091 and DRF? Researchers will use magnetic resonance imaging (MRI) scans to compare images of the brain before and after treatment. They will also explore the effect of BIIB091 and DRF on the heart using electrocardiograms (ECGs). The study will be done as follows: * After screening, participants who joined Part 1 will be randomly assigned to receive either a high or low dose of BIIB091, or the standard dose of DRF. * The results of Part 1 will be used to choose the best dose of BIIB091 to use in Part 2. * Participants who join Part 2 will be randomly assigned to receive either a standard dose of DRF, a combo of BIIB091 and the standard dose of DRF, or a combo of BIIB91 with a low dose of DRF. * Neither the researchers nor the participants will know which drug or dose the participants will receive in either part of the study. * The treatment period will last 48 weeks in each part of the study. Participants will take the drugs by mouth 2 times a day. * Each part will also have a follow-up safety period that lasts up to 2 weeks. * In total, participants in each part will have 20 study visits, or more if they have a relapse. The total study duration for participants will be up to 54 weeks.
Recruiting0 awards Phase 2
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University of Miami Miller School of Medicine?
University of Miami Miller School of Medicine is a medical facility located in Miami, Florida. This center is recognized for care of Human Immunodeficiency Virus Infection, Multiple Sclerosis, Fibrosis, HIV/AIDS, Cystic Fibrosis and other specialties. University of Miami Miller School of Medicine is involved with conducting 369 clinical trials across 405 conditions. There are 22 research doctors associated with this hospital, such as Sabine s Coppieters, MD, Marilyn Huang, Cynthia Levy, MD, and Paul Martin, MD.
Where is University of Miami Miller School of Medicine located?
**University of Miami Miller School of Medicine Hospital**
- **Address:** 1150 NW 14th St, Miami, FL 33136.
- **Directions:** Exit I-95 onto SR 836 West, then stay right to exit onto NW 12th Avenue. Continue north to enter the medical center complex at NW 16th Street.
Who should I call to ask about financial aid or insurance network?
**University of Miami Miller School of Medicine Hospital Contact Information:**
- **Financial Assistance:**
- Phone: 305-689-7079
- Email: charityrequest@miami.edu
- **Insurance Department Inquiries:**
- Phone: 305-243-2900
- Email: UHIBilling@miami.edu
What insurance does University of Miami Miller School of Medicine accept?
The University of Miami Miller School of Medicine offers a range of insurance plans. For students, Aetna Student Health is the primary provider, with an option to waive this requirement if they have an equivalent policy. Employees can choose from three medical plans: Aetna Select 1, Aetna Select 2, and the HRA.
What awards or recognition has University of Miami Miller School of Medicine received?
The University of Miami Miller School of Medicine hospital, located in Miami, Florida, is the leading institution in Florida for research funding from the National Institutes of Health. It is globally recognized for its clinical research, which contributes to innovative patient care and attracts top medical talent.